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Oral Presentations S185and umbilical cord blood (n5 48). Seventy-six percent received
myeloablative conditioning. Scores were distributed as follows:
HCT-CI5 0 (n5 185), 1-2 (n5 33) and 3+ (n5 34). Median
follow-up was 343 days (range 110-624). The 1 year cumulative
incidence of NRM increased (12%, 16% and 32%, respectively;
p5 0.02) and OS decreased (83%, 62% and 60%, respectively;
p5 0.01) with increasing HCT-CI scores. A multivariate analysis
evaluating the effect of HCT-CI on NRM showed that those with
scores of 1-2 and 3+ had a relative risk of death of 1.6 (95%CI 0.6-
4.2, p5 0.37) and 5.3 (95%CI 1.9-14.6, p\0.01) when compared
to those with a score of zero. Similarly, when evaluating OS, those
with scores of 1-2 and 3+ had a relative risk of death of 2.5
(95%CI 1.2-5.1, p5 0.01) and 4.0 (95%CI 1.7-9.0, p\0.01),
respectively. Other factors that had a significant impact on NRM
and OS include donor type and conditioning intensity. HCT-CI
score appears to predict NRM andOS in pediatric patients undergo-
ing HCT and may be a useful tool to assess risk, guide counseling in
the pre-transplant setting and devise innovative therapies for the
highest risk group.81
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Background: Allogeneic hematopoietic stem cell transplantation
(HSCT) is curative in chronic granulomatous disease (CGD) but ac-
cess to HSCT is limited by donor availability and preparative regi-
men able to induce durable donor chimerism.
Methods: Ten children (one female, 6 Caucasian, 3 CMV sero-
positive) with clinically severe CGD (x-linked, n5 6; autosomal,
n5 4) received myeloablative HSCT at our center between
1997 and 2009. Seven were previously treated with interferon.
Pretransplant morbidities included a median of 3 (range, 2-9) se-
rious bacterial/fungal infections, including one invasive pulmonary
aspergilosis treated with antifungals for .1 year, and one primary
graft failure (GF) after reduced intensity HSCT at another insti-
tution. At transplant, median age and weight were 10.25 years
(range, 0.7-11.7) and 19.6 kg (range, 9.6-60). Graft sources were
matched sibling bone marrow (SibBM) in 5, unrelated cord blood
(UCB) in 4 and sibling cord blood (SibCB) in 1 patient. SibBM
and SibCB donors were 6/6 HLA matched. UCB units were 4/
6 (n5 1) or 5/6 (n5 3) and contained a median of 3.810^7 pre-
cyropreservation nucleated cells/kg. SibBM patients received
Busulfan (Bu) and Cyclophosphamide (Cy)6ATG. Primary GF
following Bu/Cy/ATG in the first UCB recipient led to the use
of Fludarabine(Flu)/Bu/Cy/ATG in subsequent CB patients.
Five patients received irradiated granulocyte transfusions (4 from
GCSF mobilized family donors; one from Red Cross) until
engraftment.Results: Currently, all patients are alive, free of infections, doing
well (Lansky, 70-100) and have normal respiratory bursts at a me-
dian follow-up of 56 (range, 3-144) months. Two UCB recipients
developed primary GF but were successfully retransplanted with
a second UCB unit after additional conditioning with Flu/Cy
with TBI (200 cGy) or Campath. One patient developed interstitial
pneumonitis post transplant. Chimerism was all donor in 8 and
94% and 74% in the other two patients. Grade III/IV acute
GvHD developed in two and extensive chronic GvHD in 1 patient.
Conclusions: Myeloablative allogeneic HSCT with a HLA-
matched sibling or UCB donor corrects neutrophil dysfunction, re-
sults in durable high-level chimerism, and excellent survival with
minimal GvHD. Durable engraftment was acheived after second
transplant in patients who had GF after the first transplants. Patients
transplanted with UCB had equivalent outcomes to those with
HLA-matched siblings.
# of Patients %Alive and Disease Free 10 100
Most Recent Chimerism
.98% 8 80
.75% 10 100
Neutrophil Engraftment Median Range
SibCB & UCB 29 days 16-43
SibBM 16 days 11-20
Platelet Engraftment
SibCB & UCB 72 days 28-172
SibBM 40 days 33-5982
RISING NUMBERS OF RECENT THYMIC EMIGRANTS (RTE) WITHIN THE
FIRST YEAR AFTER UNRELATED CORDBLOOD TRANSPLANT (UCBT) PRE-
DICT OVERALL SURVIVAL FOR CHILDREN: A MULTIVARIATE ANALYSIS
FOLLOWING MYELOABLATIVE CONDITIONING AND A SINGLE UNIT
GRAFT
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Opportunistic infections and leukemic relapse negatively impact
overall survival after UCBT. Recovery of antiviral T cell function
correlated with reduced risk of relapse in the COBLT study, pre-
sumably due to enhanced GVL effect.
Objectives: We set out to determine if the tempo and quality of
immune recovery during the first year after UCBT can predict
survival.
Methods: A pediatric cohort (n5 93) was transplanted between
July 2005 and September 2008 at a single center. All studied pa-
tients engrafted fully following myeloablative conditioning and
a single CB graft. Immune reconstitution was monitored longitudi-
nally by a uniform 4 color FACS panel to enumerate B and NK
cells along with DC and T cell subsets. Two sided t-test was em-
ployed in univariate analyses to test for differences between the
mean values generated from all time points (n5 432) between
those alive and those who eventually died. Logistic regression
models were created comparing patients above and below the me-
dian values obtained during the first 365 days post-UCBT using
forward selection method.
Results: 63 of 93 children were transplanted for non-malignant
diseases and 19 of them were minority. The median age was 2.1
years (range 0.1 to 18), 58%were male, 36% were 4/6, 41% were
5/6, and 23% were 6/6 HLA match. Overall, 67 patients (72%)
are alive. Univariate analysis demonstrated that those who never
died had significantly more circulating CD4+, CD8 +T cells, B
cells, Tregs, RTE, and plasmacytoid DC. In this cohort where
all studied patients have already engrafted and where death was in-
frequent, gender, race, CMV serology, TNC, CD34+ cell dose,
TBI, acute GVHD 2-4 or 3-4 had no impact on overall survival.
